# Oral Civamide Safety, Tolerability First in Human Study

> **NCT00802217** · PHASE1 · TERMINATED · sponsor: **Winston Laboratories** · enrollment: 12 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Civamide
- **DRUG:** Civamide

## Key facts

- **NCT ID:** NCT00802217
- **Lead sponsor:** Winston Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2009-06
- **Final completion:** 2009-07
- **Target enrollment:** 12 (ESTIMATED)
- **Why stopped:** PK results demonstrated no systemic absorption
- **Last updated:** 2011-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00802217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00802217, "Oral Civamide Safety, Tolerability First in Human Study". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00802217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*